Wayne State University Enters License Agreement with TRImaran Pharma Inc.

 

DETROIT— Wayne State University recently entered into an exclusive license agreement with TRImaran Pharma Inc. for a class of novel drugs developed at Wayne State University that aims to offer hope in the treatment of post-traumatic stress disorders (PTSD), depression, ADHD and other neurological disorders.

Aloke Dutta, Ph.D., professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State, has developed promising lead molecules based on unique pyran molecular structures known as triple reuptake inhibitors (TRI) to address the current therapeutic need for treating depression, PTSD and other neurological disorders, including Parkinson’s disease. These drugs enhance three key monoamine neurotransmitters — serotonin, norepinephrine and dopamine — by blocking monoaminergic transporters in the brain, prolonging neurotransmitter activity between brain cells, and thereby producing therapeutic effects.

Subscribe to get the latest news